In the United States, an estimated 60-70 million people are affected by gastrointestinal disorders (GI). Celiac disease may be present despite the absence of GI symptoms, particularly, in relatives of individuals with celiac disease.1
Not surprisingly, there is an overlap between these disorders.
The CICA is a comprehensive test array that analyzes genetic predisposition, detects specific antibodies, and measures potentially inflammatory cellular reactions all through one simple blood draw.
Celiac disease risk analysis is determined based on the presence or absence of the HLA-DQ genotypes. Both the DQ8 and DQ2.5 genotypes are tested in this array, with the DQ2.5 genotypes representing a much greater risk of celiac disease.
Four specific serum antibodies (DGP IgG/IgA and tTG IgG/IgA) are tested due to their high sensitivity and specificity for active celiac disease. The higher the antibody levels, the more likely untreated celiac disease is present.
Anti-Saccharomyces Cerevisiae Antibody (ASCA; IgG/IgA) are immune proteins that are frequently present in people who have Crohn’s disease. The presence of ASCA may also reflect increased intestinal inflammation and permeability, including an association with active Crohn’s disease.
Option 1: Celiac, IBS, and Crohn’s Array (CICA)
(Genetic + Serologic)
Option 2: CICA – Genetic Only
Option 3: CICA – Serologic/Antibody Only
CICA test results are color-coded and easy to read. Each result is thoroughly explained with expert commentary.
Cell Science Systems Corp. is a specialty clinical laboratory that develops and performs testing in immunology, serology, cell biology and molecular diagnostics supporting the personalized treatment and prevention of chronic disease.
Cell Science Systems Corp. operates a CLIA licensed laboratory and is an FDA inspected and registered, cGMP medical device manufacturer meeting ISO EN13485 2012 standards.
Cell Science Systems fulfills high quality state and federal standards.
To learn more about our Celiac disease lab test process and CICA, contact Cell Science Systems today to speak with a laboratory representative.
1 Aggarwal S, Lebwohl B, Green PHR. Screening for celiac disease in average-risk and high-risk populations. Therap Adv Gastroenterol. 2012 Jan; 5(1): 37–47.
2 Hulisz D. The Burden of Illness of Irritable Bowel Syndrome: Current Challenges and Hope for the Future. J Manag Care Pharm. 2004;10(4):299-309
3 Loftus EV Jr. Clinical epidemiology of inflammatory bowel disease: Incidence, prevalence, and environmental influences. Gastroenterology. 2004 May;126(6):1504-17.
4 Gasbarrini GB, Mangiola F. Wheat-related disorders: A broad spectrum of ‘evolving’ diseases. United European Gastroenterol J. Aug 2014; 2(4): 254–262.
5 Saad RJ, Chey WD. Review article: current and emerging therapies for functional dyspepsia. Aliment Pharmacol Ther. 2006; 24, 475–492
6 Brandt LJ, Chey WD, Foxx-Orenstein AE, et al. Evidence-based position statement on the management of irritable bowel syndrome in North America. American College of Gastroenterology Functional Gastrointestinal Disorders Task Force. Am J Gastroenterol. 2009;104(Suppl 1):S1-S35.